Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.

Détails

Ressource 1Télécharger: 33266011_BIB_56B0CF596533.pdf (301.44 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_56B0CF596533
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.
Périodique
Cancers
Auteur(s)
Bonomo P., Maruelli A., Saieva C., Taylor K., Singer S., Patelli Z., Rogers S., Mattavelli D., Simon C., Scotté F., de Oliveira T.B., Murphy B., Rhoten B.A., Tassini U., Fallon M., Gatidis O.N., Yarom N., Bergamini C., Bossi P.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
30/11/2020
Peer-reviewed
Oui
Volume
12
Numéro
12
Pages
E3577
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Shared-decision making for head and neck squamous cell carcinoma (HNSCC) is challenged by the difficulty to integrate the patient perception of value within the framework of a multidisciplinary team approach. The aim of this study was to develop a questionnaire to assess the preferences of HNSCC patients with respect to the disease trajectory, expected treatment, and toxicities. In accordance with the standardized EORTC Quality of Life Group's methodology for the development of quality of life modules, a phase 1-2 study was envisaged. Following a systematic review of the literature, a consolidated list of 28 issues was administered through a semi-structured interview to 111 patients from 7 institutions in 5 countries. Overall, "cure of disease", "survival", and "trusting in health care professionals" were the 3 most common priorities, being chosen by 87.3%, 73.6% and 59.1% of patients, respectively. When assessing the correlation with the treatment subgroup, the issue of "being thoroughly and sincerely informed about treatments' efficacy and survival expectation" was highly prevalent in an independent manner (71.4%, 75% and 90% of patients in the follow-up, palliative and curative subgroups, respectively). Based on prespecified scoring criteria, a 24-item list was generated. Pending clinical applicability, further testing and validation of the questionnaire are warranted.
Mots-clé
head and neck cancer, multimodal therapies, patient preferences, patient priorities, quality of life
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/12/2020 15:30
Dernière modification de la notice
12/01/2022 7:10
Données d'usage